GNMSF OTC
Credit Risk of going bust: lower than 69% of companies Debt: 16.1% of company value Bonds: none of note held by US funds details ▾
Total debt $5.27B against a stock market value of $27.48B.
Distance to default 7.47 (Merton model): prices to 2026-10-23, balance sheet 2026-06-30, debt counted $2.71B (short-term plus half of long-term), stock volatility 35.1%; Altman Z'' 3.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Copenhagen, CD 2500
DK
Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric, esophageal, and non-small cell lung cancers. Their extensive pipeline includes daratumumab, also being explored for non-MM blood cancers and AL amyloidosis, along with GEN1047, tisotumab vedotin for cervical, ovarian, and other solid cancers, and specialized DuoBody and HexaBody platforms targeting various solid tumors and hematological malignancies, such as Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and CLL. Genmab further maintains approximately 20 active pre-clinical programs and a diverse array of compounds in Phase 2 development, investigating treatments for conditions like vaso-occlusive crises (Teclistamab), Hodgkin lymphoma and solid tumors (Camidanlumab tesirine), multiple myeloma (JNJ-64007957 and JNJ-64407564), celiac disease (PRV-015), hemophilia A (Mim8), and multiple system atrophy (Lu AF82422). The company engages in significant strategic collaborations, notably with Seagen Inc. for the co-development of tisotumab vedotin, CureVac AG for mRNA-based antibody products, and AbbVie for Epcoritamab, alongside other partnerships with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
